Moderna Stock Soars 177% as Cancer Vaccine Delivers a Landmark Phase 3 Win

Moderna shares recorded their biggest one-day gain on record after the biotechnology company and Merck announced positive Phase 3 results for a personalized mRNA cancer vaccine in patients with high-risk melanoma.

Moderna stock closed Wednesday at $174.38, surging 177.2% and reaching its highest level in three years. The rally added roughly $44 billion to the company’s market capitalization, lifting it to about $69.4 billion. Merck shares advanced 12.6% to a record $152.20. Market data showed Moderna traded almost 200 million shares during the session.

Key Takeaways

• Moderna and Merck’s personalized cancer vaccine combination met both primary endpoints in a Phase 3 melanoma trial.
• The treatment significantly improved recurrence-free survival and distant metastasis-free survival compared with Keytruda alone.
• Moderna gained 177% to $174.38, while Merck rose 12.6% to a record high.
• Detailed Phase 3 efficacy figures have not yet been released, making the full clinical presentation the next major catalyst.

Phase 3 Trial Meets Both Primary Endpoints

The INTerpath-001 study evaluated intismeran autogene, previously known as V940 or mRNA-4157, in combination with Merck’s Keytruda. The treatment was administered after surgery to patients with completely resected Stage IIB through Stage IV melanoma who remained at high risk of recurrence.

According to the companies, the combination produced statistically significant and clinically meaningful improvements in both recurrence-free survival and distant metastasis-free survival when compared with Keytruda alone. The first endpoint measures how long patients remain alive without their cancer returning, while the second tracks whether the disease spreads to another part of the body.

No unexpected safety findings were identified, and the treatment’s safety profile remained consistent with previous studies. However, Moderna and Merck did not disclose the Phase 3 hazard ratios, absolute survival rates or overall-survival results. The companies plan to present the complete findings at an international medical conference and discuss potential regulatory submissions with health authorities. Merck’s official announcement described the result as supporting a more personalized approach to cancer treatment.

How Moderna’s Personalized Cancer Vaccine Works

Intismeran is a therapeutic cancer vaccine rather than a preventive vaccine. Doctors first analyze genetic material from an individual patient’s tumor to identify mutations unique to that cancer. Moderna then produces a customized dose containing synthetic mRNA instructions for as many as 34 tumor-specific neoantigens.

The goal is to train the patient’s immune system to recognize and attack cells carrying those mutations. Keytruda, meanwhile, blocks the PD-1 pathway that cancer cells can use to suppress the immune response. Combining the two treatments is intended to help the immune system identify the cancer while removing one of the mechanisms that allows malignant cells to escape detection.

The individualized manufacturing process represents both the program’s main scientific advantage and a potential commercial challenge. Every treatment must be designed and produced for a specific patient, creating questions about manufacturing speed, cost, reimbursement and large-scale distribution.

Earlier Results Set a High Bar

Earlier Phase 2 findings had already made the program one of Moderna’s most valuable non-COVID assets. In that study, intismeran plus Keytruda reduced the risk of recurrence or death by 49% and lowered the risk of distant metastasis or death by 59% compared with Keytruda alone.

Those figures must not be confused with the new Phase 3 outcome, for which the detailed risk reductions remain undisclosed. Nevertheless, meeting both late-stage endpoints provides stronger confirmation that the benefit observed in the smaller study was not a statistical anomaly. Analysts described the result as the first positive Phase 3 readout for an individualized neoantigen therapy. Investor’s Business Daily reported that some analysts estimate the melanoma opportunity could eventually be worth around $2.5 billion.

Short Covering Amplifies Moderna’s 177% Rally

The clinical breakthrough was the fundamental catalyst, but market positioning likely magnified the move. Around 13.7% of Moderna’s publicly traded shares had been sold short before the announcement, leaving bearish investors exposed to a sharp squeeze when the positive result arrived.

Moderna’s gain lifted its 2026 advance to approximately 445%, although the stock remains well below its August 2021 record near $484. The rally also spread across the mRNA sector, with BioNTech climbing more than 20% as investors reassessed the broader potential of personalized cancer vaccines.

The result could help Moderna establish a major business beyond respiratory vaccines. The company and Merck are already studying the technology in other tumor types, including lung, kidney and bladder cancers. Still, the market will need the full Phase 3 dataset before determining the treatment’s precise clinical and commercial value.

Investors will now focus on the magnitude and durability of the benefit, patient subgroups, manufacturing readiness and the regulatory timetable. Analysts have suggested a possible US approval in 2027, but that remains an expectation rather than confirmed guidance. Moderna’s 177% rally reflects a genuine scientific milestone, yet converting that breakthrough into a scalable and profitable oncology franchise will be the company’s next test.

Explore Stock CFDs with Markets.com and trade price movements across leading global companies. Claim up to $5,000 in bonuses and start trading today.